UBS Group AG lowered its position in shares of Cellectis S.A. (NASDAQ:CLLS) by 82.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,890 shares of the biotechnology company’s stock after selling 38,248 shares during the period. UBS Group AG’s holdings in Cellectis were worth $189,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of CLLS. Sphera Funds Management LTD. acquired a new position in Cellectis during the first quarter valued at approximately $3,832,000. Trexquant Investment LP acquired a new position in Cellectis during the first quarter valued at approximately $214,000. Vident Investment Advisory LLC boosted its position in Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock valued at $1,224,000 after buying an additional 8,496 shares during the period. Finally, Eqis Capital Management Inc. acquired a new position in Cellectis during the first quarter valued at approximately $202,000. 16.06% of the stock is owned by institutional investors.
Cellectis S.A. (CLLS) opened at 22.02 on Friday. Cellectis S.A. has a 52 week low of $16.09 and a 52 week high of $28.77. The company’s market cap is $789.68 million. The company’s 50-day moving average price is $24.74 and its 200 day moving average price is $23.57.
WARNING: This story was originally posted by BNB Daily and is the property of of BNB Daily. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/19/cellectis-s-a-clls-position-decreased-by-ubs-group-ag-updated.html.
Several equities analysts recently issued reports on CLLS shares. Jefferies Group LLC restated a “buy” rating and set a $47.00 price objective on shares of Cellectis in a research note on Wednesday, April 26th. BidaskClub cut Cellectis from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Zacks Investment Research raised Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a research report on Wednesday, July 19th. Finally, Oppenheimer Holdings, Inc. set a $40.00 target price on Cellectis and gave the stock a “buy” rating in a research report on Wednesday, May 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $41.80.
Cellectis Company Profile
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.
Receive News & Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related companies with MarketBeat.com's FREE daily email newsletter.